Subtypes of breast cancer show preferential site of relapse.

By Marcel Smid, Yixin Wang, Yi Zhang, Anieta M. Sieuwerts, Jack Yu, J. Klijn, John A. Foekens, John W. M. Martens. Cancer Research, 2008

805 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/0e22fb431744826a014a63149cd130decdfbbeec

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. J. Massagué
2. J. Reis-Filho
3. A. Richardson
4. Frederick L. Baehner
5. Ian O. Ellis
6. A. Lluch
7. Zhonghu Bai
8. Xiaofeng Dai

In Molecular Biology

1. X. Zhang
2. Larry Norton
3. Thordur Oskarsson
4. A. Richardson
5. Qiongqing Wang
6. J. Reis-Filho
7. A. Lluch
8. J. Massagué

In Oncology

1. J. Massagué
2. X. Zhang
3. Larry Norton
4. Thordur Oskarsson
5. J. Reis-Filho
6. A. Richardson
7. Swarnali Acharyya
8. Zhonghu Bai

Citations in the corpus

• Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists (2011, background): “119 with a peculiar proclivity to develop metastatic deposits in the brain and lungs”
• Latent bone metastasis in breast cancer tied to Src-dependent survival signals (2009, methodology): “Molecular subtype classification was done as previously described (Smid et al., 2008) according to published classifiers (Perou et al.”
• Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. (2012, background): “The pattern of metastatic relapse is aggressive with predominance for visceral organs, mainly lung, central nervous system and lymph nodes.(20,36) One of the most relevant features of this type of tumor is the absence of expression of the three key receptors in breast cancer: ER, PGR and HER2 (Fig.”
• Breast cancer intrinsic subtype classification, clinical use and future trends. (2015, background): “8% of all breast cancer cases in a lymph-node negative cohort [15], shares a similar IHC status with the luminal A subtype and are characterized by a normal breast tissue profiling [16].”
• Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs (2011, methodology): “These TNC signature probes were used to cluster the microarray data of 344 primary breast tumors (GSE2603 and GSE5327 combine”
• An overview of triple-negative breast cancer (2016, background): “Survival after metastatic relapse is also shorter in TNBC compared to other subtypes and this can be explained by the predilection for visceral and lung metastasis compared with ER-positive breast cancers that are more likely to relapse in the bone and skin [74, 77].”